SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a notable surge driven by institutional inflows and a massive short squeeze that has liquidated significant bearish positions. The community is buzzing over potential positive regulatory developments from White House discussions and the impact of Treasury bond buyback policies, with many bulls sensing the end of a long consolidation period.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing a historic surge driven by positive Phase 3 results for its personalized melanoma cancer vaccine, sparking a massive short squeeze that has captivated retail and institutional investors. Community discourse is polarized, featuring a mix of celebration over the potential medical breakthrough and intense skepticism regarding the company's long-term commercialization timeline and the likelihood of imminent stock dilution.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors speculate on a potential buyout by a consortium led by Nelson Peltz, fueling intense debate between those anticipating a short squeeze and those skeptical of the deal's viability. The community remains hyper-focused on elevated short interest and upcoming leadership changes, with many actively discussing whether the current price action signals an imminent move.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion is trending as investors react to active share buybacks and Ethereum accumulation, while community sentiment remains highly polarized between those betting on a short squeeze driven by institutional rotation and those skeptical of management's history of dilution. Debates are heavily focused on the stock's potential as a leveraged play on Ethereum compared to the risks associated with stalled legislative clarity and the company's past capital-raising decisions.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to rising institutional ownership and growing optimism regarding its upcoming Biologics License Application (BLA) filing for aglatimagene in late 2026. The community is actively discussing potential M&A scenarios and the company's progress in clinical trials, fueling speculation about its long-term valuation.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum as investors speculate on institutional accumulation, including recent interest from political figures and large-scale holdings by major tech companies. Community discourse is currently focused on the company's potential for a short squeeze given its high short interest, while bullish sentiment is further supported by the strategic value of its data-driven precision oncology platform and key biopharma partnerships.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as institutional ownership rises to approximately 91%, signaling strong accumulation despite the stock's recent volatility. Investors are actively debating the company's long-term licensing strategy and potential for a strategic buyout, particularly as they await milestones from the Sanofi partnership and developments surrounding the Matrix-M adjuvant platform.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is seeing significant retail attention and elevated volatility ahead of its upcoming earnings report, with the community actively debating whether the stock will break out toward double digits or suffer a post-earnings selloff similar to peers. Bullish traders are pointing to institutional accumulation and technical setups like a potential golden cross, while bears remain skeptical of the company's valuation and history of earnings reactions.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is capturing significant market attention as it reaches new highs, fueled by a breakout in commercial momentum and positive analyst revisions following a strong earnings report. Investors are actively discussing the potential for a short squeeze and the strategic appeal of the company's TIL therapy platform as a prime candidate for acquisition within the oncology sector.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is trending as investors digest news of its cancer-fighting collaboration with Moderna, which met its primary endpoint in a major clinical trial. The market is actively debating Merck's strategic positioning and potential for future oncology acquisitions as it looks to bolster its pipeline before key patent expirations.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oil Tops $100 First Time Since May: ETFs to Top & Flop

Brent crude topped $100 for the first time since May as Middle East tensions escalated. Here's which ETFs could benefit and which may come under pressure.

Oil Slides as Trump Delays Planned Strike on Iran: ETFs to Win

Oil prices slid after Trump delayed a planned Iran strike, boosting prospects for retail, airline, India and gold mining ETFs.

ETFs to Play Amid Hopes of Middle East De-escalation

Middle East truce hopes drag oil lower, lifting refiners, airlines, retail & India ETFs -- but fragile peace keeps risks alive.

Is India Well-Positioned Despite a Cautious Market? ETFs to Consider

India's resilient growth outlook and easing conflict fears are lifting sentiment, while a nuclear energy push strengthens the case for India ETFs.

Spotlight on Indian ETFs as RBI Holds Rates Amid Middle East Crisis

INDA and peers gain traction as RBI holds rates amid Middle East tensions, with resilient Indian equities drawing investor attention to diversified exposure.  

Iran War: Energy Damage Could Make or Break India ETFs

India ETFs slide as weak domestic demand and Iran war risks weigh, but easing oil prices and stable inflation (if war eases) could revive growth.

Is Energy Market Complacent Amid Oil's Backwardation? ETFs in Focus

Oil's backwardation hints at calm - but is the market too complacent? ETFs may face mixed moves as geopolitical risks and supply damage linger.

Oil Prices to Stay High for Long? ETFs to Gain/Lose

Oil tops $110 as Middle East tensions persist. Goldman Sachs sees elevated prices through 2027 -- energy ETFs gain while retail, airlines lag.

Reliance Industries to Fund $300B US Refinery: India ETFs in Focus 

Reliance Industries is set to fund a $300B Texas refinery, a move that could boost India ETFs holding the conglomerate.

ETF Areas to Win/Lose Amid Middle East Tensions

Oil spikes on Middle East tensions. Energy & shipping ETFs may rally, while airlines, retail and refiners could face pressure.

iShares Trust - iShares India 50 ETF

Trump’s Trade Representative Says More Talks Needed With India As August Tariff Deadline Nears 

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

INDYiShares India 50 ETF

Fundamentals

Connect Stocktwits to ChatGPT

Latest INDY News